- Konferenz
Cherwell to demonstrate new EM product pipeline at Pharmaceutical Microbiology Europe conference
Company will highlight how it can support Environmental Monitoring programmes as part of contamination control strategies, in line with Annex 1
Cherwell, specialists in cleanroom microbiology solutions for the pharmaceutical, healthcare and related industries, will be exhibiting and discussing the latest additions to its high-quality range of environmental monitoring (EM) products at the Pharmaceutical Microbiology Europe Conference, in London, 16-17 January 2023.
This is the first time that Cherwell will attend this annual conference, so it will provide an opportunity for delegates from the pharmaceutical and cell & gene therapy industry to preview some of the very latest EM solutions currently in the Company’s product pipeline. These are all specifically designed to support EM programmes as part of contamination control strategies in line with the recently published EU GMP Annex 1 governing the manufacture of sterile medicinal products within the UK and Europe.
Uncovering key developments and discussing the future of microbiology as an essential tool for the detection of microorganisms present in biopharmaceutical and drug product manufacture, the conference will have a strong focus on the impact of Annex 1, alongside new pharmaceutical microbiology technologies. In particular, presentations from key pharmaceutical manufacturers will discuss the initial challenges that Annex 1 has presented and the transformations required in companies’ contamination control strategies in order to secure full compliance. There will also be case study examples and a group discussion session to benchmark impact of Annex 1 across the industry to date.
The products and solutions offered by Cherwell are aligned with a number of presentation topics and cover all graded spaces (A – D). For example, the SAS air sampling range is reliable and robust equipment known to conform to the Annex 1 requirement of 1m³ sampling. Additionally, the new ImpactAir® air monitor range is designed for high-risk graded environments, deploying a continuous viable air monitoring innovation known as ‘slit to agar’. The process provides assurances on potential contamination within the cleanroom environment with a D50 value of 0.53 micron, capturing extremely small-scale particles and complying with Annex 1 requirements.
Cherwell’s cleanroom microbiology experts will be available on its exhibition stand at Pharmaceutical Microbiology Europe to offer practical advice and demonstrate solutions that can be tailored to meet individual customers’ specific microbiological monitoring and validation requirements.
“We work in partnership within the market and take pride in sharing our knowledge, experience and expertise to ensure that everyone is using our portfolio in the best way possible for their environmental needs and expectations,” said Thomas Parkhill, Business Development Manager- South, Cherwell Laboratories. “While we’re experts in the area of EM, we’re really looking forward to hearing the presentations at the conference from experts in a number of other fields within the industry to help us further expand our breadth and depth of knowledge in the industry.”
With over 50 years of experience, Cherwell has built a reputation within the pharmaceutical and healthcare sciences industry as a provider of high-quality products to meet the specific requirements of environmental monitoring and process validation. In addition to the ImpactAir continuous viable air monitoring solutions and SAS microbial air samplers for active environmental monitoring, Cherwell manufactures and supplies the Redipor® prepared media range, comprising agar plates, bottled media, vials, broth bags and ampoules.
Cherwell Laboratories Ltd
OX26 4XB BICESTER
Vereinigtes Königreich